DTMT Network

It seems that the risk of type 2 diabetes is reduced by Alendronate, according to a study presented at the annual meeting of the European Association for the Study of Diabetes.

The annual meet is being held virtually from September 28, 2021, to October 1, 2021.

A population-based case-control study was conducted to examine whether the risk for developing type 2 diabetes is altered by previous alendronate use

It was conducted by Rikke Viggers and Peter Vestergaard, M.D., Ph.D., from Aalborg University Hospital in Denmark.

All cases with a diagnosis of type 2 diabetes between 2008 and 2018 were matched with three randomly selected controls based on sex and age by incidence-density sampling.

Statistics were involved for 163,588 patients with type 2 diabetes and 490,764 matched controls.

The authors found that after alendronate use, the crude odds ratio for developing type 2 diabetes was 0.93; this was further reduced after adjustment (multiple adjusted odds ratio, 0.64).

Among those with more than eight years of alendronate use, the adjusted odds ratio attenuated to 0.47.

There was a dose-response relationship recorded between longer effective alendronate use and a reduced risk for type 2 diabetes.

“Excitingly, our research suggests that alendronate, an inexpensive medicine widely used to treat osteoporosis, may also protect against type 2 diabetes. We believe that doctors should consider this when prescribing osteoporosis drugs to those with pre-diabetes or at high risk of type 2 diabetes,” Viggers said in a statement.